Genetically Assessed Risk Factors of Colorectal Cancer: a Literature Review of Mendelian Randomization Study
DOI:
https://doi.org/10.53366/jimki.v12i2.905Keywords:
Colorectal cancer, Risk factors, Mendelian randomizationAbstract
Introduction: Colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related mortality globally. Despite substantial progress, the causal mechanisms linking various risk factors to CRC remain unclear due to confounding and reverse causality in observational studies. Mendelian Randomization (MR), which utilizes genetic variants as instrumental variables, offers a robust alternative for inferring causal relationships.
Method: This narrative literature review evaluates MR studies published in the last decade that investigated genetically predicted risk factors associated with CRC. Articles were selected through systematic searches using PubMed and Cochrane databases. Inclusion criteria comprised relevance to CRC, MR methodology, full-text availability, and publication in peer-reviewed journals.
Discussion: A total of seven MR studies were analyzed. The findings indicated that higher levels of total bilirubin, epigenetic clock GrimAge acceleration, insulin-like growth factor-1 (IGF-1), alcohol consumption, air pollutants (PM2.5), and specific gut microbiota (e.g., Porphyromonadaceae, Anaerotruncus, Intestinibacter) were causally associated with increased CRC risk. Conversely, Gammaproteobacteria and Enterobacteriaceaeappeared protective. While MR reduces confounding and reverse causality, limitations such as horizontal pleiotropy and ancestry-specific biases (primarily European and East Asian populations) may affect generalizability, particularly to Southeast Asian populations.
Conclusion: Genetically predicted exposures including biochemical markers, microbiota, and environmental factors demonstrate significant causal associations with CRC. However, future MR studies involving Southeast Asian populations, especially Indonesians, are needed to validate these findings within different genetic and environmental contexts.
References
1. Recio-Boiles A, Waheed A, Cagir B. Colon cancer [Internet]. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/bo oks/NBK470380/
2. Rawla P, Sunkara T, Barsouk A. Epidemiology of Colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Review. 2019. 14(2).
3. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024. Available from: https://gco.iarc.who.int/today [accessed 24 September 2024].
4. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017. 66(4):683–691.
5. Carethers JM, Doubeni CA. Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies. Gastroenterology. 2020.158(2):354-367.
6. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019. 14(2):89-103.
7. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021. 13(9):2025.
8. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011. 128(1):305-310.
9. Sanson-Fisher, R. W., Bonevski, B., Green, L. W., & D'Este, C.. Limitations of the randomized controlled trial in evaluating population-based health interventions. American journal of preventive medicine. 2007. 33(2):155–161.
10. Guo JZ, Xiao Q, Gao S, Li XQ, Wu QJ, Gong TT. Review of Mendelian Randomization Studies on Ovarian Cancer. Frontiers in Oncology. 2021.11.
11. Go TH, Kang DR. Basic Concepts of a Mendelian Randomization Approach. Cardiovascular Prevention and Pharmacotherapy. 2020. 2(1):24.
12. Markozannes G, Kanellopoulou A, Dimopoulou O, Kosmidis D, Zhang X, Wang L, et al. Systematic review of Mendelian randomization studies on risk of cancer. BMC Medicine. 2022. 20(1).
13. Seyed Khoei N, Jenab M, Murphi N, et al. Circulating bilirubin levels and risk of colorectal cancer: serogogical and Mendelian randomization analyses. BMC Med. 2020. 18(1):229.
14. Vitek L, Jirásková a., Malíková I, Dostálová G, Eremiášová L, Danzig V, Linhart A, Haluzík M. Serum Bilirubin and Markers of Oxidative Stress and Inflammation in a Healthy Population and in Patients with Various Forms of Atherosclerosis. Antioxidants (Basel). 2022. 11(11):2118.
15. Ioannou GN, Liou IW, Weiss NS. Serum bilirubin and colorectal cancer risk: a population-based cohort study. Aliment Pharmacol Ther. 2006. 23(11):1637–42.
16. Morales Berstein F, McCartney DL, Lu AT, Tsilidis KK, Bouras E, Haycock P, Burrows K, Phipps AI, Buchanan DD, Cheng I; PRACTICAL consortium; Martin RM, Davey Smith G, Relton CL, Horvath S, Marioni RE, Richardson TG, Richmond RC. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. eLife. 2022. 11:e75374.
17. Dugué PA, Bassett JK, Wong EM, Joo JE, Li S, Yu C, Schmidt DF, Makalic E, Doo NW, Buchanan DD, Hodge AM, English DR, Hopper JL, Giles GG, Southey MC, Milne RL. Biological Aging Measures Based on Blood DNA Methylation and Risk of Cancer: A Prospective Study. JNCI Cancer Spectr. 2020. 5(1):pkaa109.
18. Hillary RF, Stevenson AJ, McCartney DL, Cambell A, Walker RM, Howard DM, Ritchie CW, Horvath S, Hayward C, McIntosh AM, Porteous DJ, Deary IJ, Evans KL, Marioni RE. Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden. Clinical Epigenetics. 2020. 12:115.
19. Morales B, Fernanda et al. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. eLife. 2022. 11:e375374.
20. Xiang Y, et al. Identification of host gene-microbiome associations in colorectal cancer patients using Mendelian randomization. Journal of translational medicine. 2023. 21:1535.
21. Yang J, McDowell A, Kim EK, et al. Development of a colorectal cancer diagnostic model and dietary risk assessment through gut microbiome analysis. Exp Mol Med. 2019. 51:1-15.
22. Loke MF, Chua EG, Gan HM, et al. Metabolomics and 16S rRNA sequencing of human colorectal cancers and adjacent mucosa. PloS ONE. 2018. 13(12).
23. Li W, et al. Exploring the Complex Relationship between Gut Microbiota and Risk of Colorectal Neoplasia Using Bidirectional Mendelian Randomization Analysis. Cancer epidemiology Biomarkers & Prevention. 2023. 32, 6:809-1817.
24. Alomair AO, Masoodi I, Alyamani EJ, Allehibi AA, Qutub AN, Alsayari KN, et al. Colonic mucosal microbiota in colorectal cancer: a single-center metagenomic study in Saudi Arabia. Gastroenterol Res Pract 2018. 5284754
25. Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome. 2016. 4:69.
26. Xu K, Jiang B. Analysis of mucosa-associated microbiota in colorectal cancer. Med Sci Monit 2017. 23:4422–30.
27. Zhou X, Wang L, Xiao J, Sun J, Yu L, Zhang H, Meng X, Yuan S, Timofeeva M, Law PJ, Houlston RS, Ding K, Dunlop MG, Theodoratou E, Li X. Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis. Int J Cancer. 2022. 151(1):83-94.
28. Jiang, Fangyuan et al. “Impact of ambient air pollution on colorectal cancer risk and survival: insights from a prospective cohort and epigenetic Mendelian randomization study.” EBioMedicine. 2024. 103:105126.
29. Ma, Qin-Yun et al. “Exposure to particulate matter 2.5 (PM2.5) induced macrophage-dependent inflammation, characterized by increased Th1/Th17 cytokine secretion and cytotoxicity.” International immunopharmacology. 2017. 50: 139-145.
30. Wang B, Wang M, Ao D, Wei X. CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer. Biochim Biophys Acta Rev Cancer. 2022. 1877(5): 188799.
31. Zhao GN, Tian ZW, Tian T, et al. TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. Cell Metab. 2021. 33(8):1640–16454.e8.
32. Rojas-Rivera D, Hetz C. TMBIM protein family: ancestral regulators of cell death. Oncogene. 2015. 34(3):269–280.
33. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: a link between exposure and inflammatory disease. Gut Microb. 2014. 5(2):215–219.
34. Zhou X, Wang L, Xiao J, Sun J, Yu L, Zhang H, Meng X, Yuan S, Timofeeva M, Law PJ, Houlston RS, Ding K, Dunlop MG, Theodoratou E, Li X. Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis. Int J Cancer. 2022. 151(1):83-94.
35. Rossi M, Jahanzaib Anwar M, Usman A, Keshavarzian A, Bishehsari F. Colorectal Cancer and Alcohol Consumption-Populations to Molecules. Cancers (Basel). 2018. 10(2):38.
36. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018. 282:121-150
37. Koyanagi YN, Nakatochi M, Ito H, et al. Genotype-stratified GWAS meta-analysis reveals novel loci associated with alcohol consumption. medRxiv. 2021.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Thariq Muabbad, Noor Qurais, Adinda Fakhihah, Felicia Virginia Thios

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




